HRS9531 Injection Placebo
Phase 1
HRS9531 Injection Placebo is one of 3 therapeutic programs targeting Overweight and Obesity. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Overweight and Obesity
#DrugCompanyPhaseTrials
1AZD9550
AstraZenecaPreclinical
LAE102 IV
LLaekna Limited
Phase 1
HRS9531 Injection Placebo
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial
Overweight and Obesity1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HRS9531 Injection Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]